Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
192
394
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Balance Sheet
Balance Sheet Decomposition
Diagnos Laboratorium Utama PT Tbk
| Current Assets | 95.6B |
| Cash & Short-Term Investments | 9.7B |
| Receivables | 50.6B |
| Other Current Assets | 35.3B |
| Non-Current Assets | 194.8B |
| Long-Term Investments | 13B |
| PP&E | 174.4B |
| Intangibles | 1.3B |
| Other Non-Current Assets | 6.1B |
| Current Liabilities | 28.3B |
| Accounts Payable | 11.6B |
| Accrued Liabilities | 2.7B |
| Other Current Liabilities | 14B |
| Non-Current Liabilities | 65.6B |
| Long-Term Debt | 62.9B |
| Other Non-Current Liabilities | 2.7B |
Balance Sheet
Diagnos Laboratorium Utama PT Tbk
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
1 303
|
1 537
|
1 393
|
16 538
|
44 720
|
28 011
|
10 245
|
|
| Cash |
1 303
|
1 537
|
1 393
|
16 538
|
44 720
|
28 011
|
10 245
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
6 507
|
2 543
|
1 696
|
|
| Total Receivables |
4 978
|
8 365
|
7 451
|
81 273
|
73 939
|
49 455
|
45 252
|
|
| Accounts Receivables |
4 951
|
8 321
|
7 433
|
50 816
|
41 730
|
42 422
|
38 280
|
|
| Other Receivables |
27
|
44
|
18
|
30 457
|
32 209
|
7 033
|
6 972
|
|
| Inventory |
928
|
1 074
|
2 123
|
5 813
|
7 760
|
6 567
|
5 142
|
|
| Other Current Assets |
0
|
160
|
452
|
1 530
|
20 938
|
31 798
|
25 470
|
|
| Total Current Assets |
7 210
|
11 136
|
11 420
|
105 154
|
153 864
|
118 373
|
87 805
|
|
| PP&E Net |
493
|
9 144
|
16 365
|
20 108
|
87 107
|
109 219
|
164 248
|
|
| PP&E Gross |
493
|
9 144
|
16 365
|
20 108
|
87 107
|
109 219
|
164 248
|
|
| Accumulated Depreciation |
217
|
626
|
2 882
|
6 724
|
13 813
|
27 047
|
30 100
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
681
|
720
|
|
| Note Receivable |
709
|
4 084
|
28 138
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
8 445
|
12 951
|
|
| Other Long-Term Assets |
76
|
74
|
3 300
|
7 313
|
1 012
|
3 218
|
5 750
|
|
| Total Assets |
8 488
N/A
|
24 439
+188%
|
59 222
+142%
|
132 575
+124%
|
241 983
+83%
|
239 936
-1%
|
271 475
+13%
|
|
| Liabilities | ||||||||
| Accounts Payable |
2 545
|
1 952
|
2 035
|
15 825
|
4 524
|
3 078
|
6 090
|
|
| Accrued Liabilities |
13
|
140
|
393
|
140
|
3 125
|
1 556
|
3 178
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
113
|
5 224
|
563
|
767
|
2 966
|
4 140
|
4 255
|
|
| Other Current Liabilities |
561
|
3 463
|
6 125
|
13 880
|
16 013
|
1 718
|
920
|
|
| Total Current Liabilities |
3 232
|
10 779
|
9 116
|
30 612
|
26 628
|
10 492
|
14 444
|
|
| Long-Term Debt |
1 757
|
98
|
3 127
|
2 188
|
10 451
|
17 330
|
59 285
|
|
| Deferred Income Tax |
0
|
0
|
7
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
281
|
296
|
512
|
708
|
3 103
|
1 686
|
2 156
|
|
| Total Liabilities |
5 270
N/A
|
11 173
+112%
|
12 763
+14%
|
33 508
+163%
|
40 182
+20%
|
29 508
-27%
|
75 885
+157%
|
|
| Equity | ||||||||
| Common Stock |
250
|
1 000
|
25 000
|
25 000
|
31 250
|
31 250
|
31 250
|
|
| Retained Earnings |
2 979
|
12 244
|
21 519
|
74 205
|
132 509
|
145 173
|
131 518
|
|
| Additional Paid In Capital |
29
|
29
|
29
|
29
|
36 707
|
36 707
|
36 707
|
|
| Other Equity |
40
|
7
|
88
|
168
|
1 335
|
2 702
|
3 884
|
|
| Total Equity |
3 218
N/A
|
13 266
+312%
|
46 459
+250%
|
99 066
+113%
|
201 800
+104%
|
210 428
+4%
|
195 590
-7%
|
|
| Total Liabilities & Equity |
8 488
N/A
|
24 439
+188%
|
59 222
+142%
|
132 575
+124%
|
241 983
+83%
|
239 936
-1%
|
271 475
+13%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
1 250
|
1 250
|
1 250
|
1 000
|
1 250
|
1 250
|
1 250
|
|
You don't have any saved screeners yet
